Conculsion
- CCNE1 amplification rates in HGSOC and EMCA depend on calling method
- CCNE1 CN may increase with emergence of treatment resistance suggesting re-biopsy at time of progression may be warranted to guide therapy options
- There are increased rates of CCNE1 amplification in Black/African American compared to white women for all tumor types but statistically significant in serous EMCA and endometrioid EMCA
- PIK3CA, ARID1A, PTEN, KRAS, NF1, and RB1 mutations were inversely associated with CCNE1 amplification
- CCNE1 is significantly likely to co-occur with ERBB2 amplification, especially in endometrioid EMCA
- CCNE1 amplified tumors appear overall non-immunogenic
- While there is some overlap with FOLR1+ and HER2+ other targeted agents will be needed to exploit CCNE1 amplification